[go: up one dir, main page]

WO2022237843A1 - Inhibiteur d'axl - Google Patents

Inhibiteur d'axl Download PDF

Info

Publication number
WO2022237843A1
WO2022237843A1 PCT/CN2022/092266 CN2022092266W WO2022237843A1 WO 2022237843 A1 WO2022237843 A1 WO 2022237843A1 CN 2022092266 W CN2022092266 W CN 2022092266W WO 2022237843 A1 WO2022237843 A1 WO 2022237843A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
compounds
int
axl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/092266
Other languages
English (en)
Chinese (zh)
Inventor
谢雨礼
吴应鸣
钱立晖
樊后兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Priority to CN202280034595.5A priority Critical patent/CN117412953A/zh
Publication of WO2022237843A1 publication Critical patent/WO2022237843A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.
  • inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-butanediol, dimethylformamide and

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une classe d'inhibiteurs d'Axl. L'invention concerne en particulier de nouveaux composés représentés par les formules (1), (2), (3) et (4), et/ou des sels pharmaceutiquement acceptables de ceux-ci, et une composition contenant les composés représentés par les formules (1), (2), (3) et (4), et/ou un sel pharmaceutiquement acceptable de ceux-ci, leur procédé de préparation et leur utilisation en tant qu'inhibiteur d'Axl dans la préparation de médicaments antitumoraux.
PCT/CN2022/092266 2021-05-12 2022-05-11 Inhibiteur d'axl Ceased WO2022237843A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280034595.5A CN117412953A (zh) 2021-05-12 2022-05-11 Axl抑制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110518860 2021-05-12
CN202110518860.4 2021-05-12

Publications (1)

Publication Number Publication Date
WO2022237843A1 true WO2022237843A1 (fr) 2022-11-17

Family

ID=84028126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/092266 Ceased WO2022237843A1 (fr) 2021-05-12 2022-05-11 Inhibiteur d'axl

Country Status (2)

Country Link
CN (1) CN117412953A (fr)
WO (1) WO2022237843A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033196A1 (fr) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Inhibiteurs de la kinase de met
WO2008048375A1 (fr) * 2006-05-19 2008-04-24 Bayer Healthcare Ag Dérivés de pyridonecarboxamide utiles pour traiter des troubles hyperprolifératifs et liés à l'angiogenèse
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
EP3239147A1 (fr) * 2014-12-25 2017-11-01 Ono Pharmaceutical Co., Ltd. Dérivé de quinoléine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033196A1 (fr) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Inhibiteurs de la kinase de met
WO2008048375A1 (fr) * 2006-05-19 2008-04-24 Bayer Healthcare Ag Dérivés de pyridonecarboxamide utiles pour traiter des troubles hyperprolifératifs et liés à l'angiogenèse
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
EP3239147A1 (fr) * 2014-12-25 2017-11-01 Ono Pharmaceutical Co., Ltd. Dérivé de quinoléine

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras

Also Published As

Publication number Publication date
CN117412953A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
JP7773987B2 (ja) スピロ環含有キナゾリン化合物
CN114901661B (zh) 新型K-Ras G12C抑制剂
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
WO2022237843A1 (fr) Inhibiteur d'axl
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
JP2023508482A (ja) スピロ環含有キナゾリン化合物
WO2020259432A1 (fr) Inhibiteur de kras-g12c
WO2022214102A1 (fr) Composé hétérocyclique agissant comme inhibiteur de kras g12d
WO2023280280A1 (fr) Composé à cycle fusionné agissant en tant qu'inhibiteur de kras g12d
WO2023138541A1 (fr) Inhibiteur de parp picolinamide, son procédé de préparation et son utilisation médicale
CN115785068A (zh) Kif18a抑制剂
WO2023061406A1 (fr) Inhibiteur de parp contenant une structure tricyclique condensée, son procédé de préparation et son utilisation médicale
WO2023041055A1 (fr) Inhibiteur de kif18a
JP6894917B2 (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
WO2023016529A1 (fr) Dérivé de naphtyridine utile comme inhibiteur de l'atr et son procédé de préparation
CN107382966B (zh) 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途
WO2022063297A1 (fr) Dérivé de quinazoline, son procédé de préparation et son utilisation
WO2022012593A1 (fr) Composé 5,6-dihydropyrazino[2,3-c]isoquinoléine
WO2015113521A1 (fr) Composé de quinazolinone deutéré et composition pharmaceutique le comprenant
WO2023051717A1 (fr) Composé cyclique fusionné agissant en tant qu'inhibiteur de shp2
CN115867542B (zh) 新型苯并咪唑化合物
EP4169915A1 (fr) Forme cristalline de composé
WO2022171088A1 (fr) Dérivé de pyrazolo[3,4-d]pyrimidin-3-one
WO2022171126A1 (fr) Composé cyclique fusionné utilisé comme inhibiteur de wee-1
WO2023083373A1 (fr) Composé utilisé comme inhibiteur de src

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22806805

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280034595.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22806805

Country of ref document: EP

Kind code of ref document: A1